TBPH - Theravance Biopharma GAAP EPS of -$0.17 revenue of $15.7M
2023-11-07 16:51:13 ET
More on Theravance Biopharma
- Theravance: Positive Findings Boost Ampreloxetine Development
- Theravance, Mylan settle patent litigation over COPD drug Yupelri
- Seeking Alpha’s Quant Rating on Theravance Biopharma
For further details see:
Theravance Biopharma GAAP EPS of -$0.17, revenue of $15.7M